Open AccessAddition of Anti-CD40 Monoclonal Antibody to Nonmyeloablative Conditioning With Belatacept Abrogated Allograft Tolerance Despite Induction of Mixed Chimerism
Author(s) -
Tetsu Oura,
Kiyohiko Hotta,
Ivy A. Rosales,
A. Dehnadi,
Kento Kawai,
Hang Lee,
A. Benedict Cosimi,
Tatsuo Kawai
Publication year - 2019
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002417
Subject(s) - belatacept , immunosuppression , immunology , regimen , transplantation , monoclonal antibody , medicine , kidney transplantation , mixed lymphocyte reaction , monoclonal , antibody , t cell , immune system , kidney transplant
We recently reported anti-CD40 monoclonal antibody and rapamycin (aCD40/rapa) to be a reliable, nontoxic, immunosuppressive regimen for combined islet and kidney transplantation (CIKTx) in nonhuman primates. In the current study, we attempted to induce allograft tolerance through the mixed chimerism approach using a conditioning regimen with aCD40 and belatacept (Bela).